Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

300
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
300
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased Levels of Serum Eosinophil-Derived Neurotoxin in Patients With Chronic Spontaneous Urticaria.

Allergy, asthma & immunology research·2026
Same author

Endotype Classification of Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease According to Chronic Rhinosinusitis Comorbidity.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Eperisone-induced immediate hypersensitivity reactions.

The Korean journal of internal medicine·2026
Same author

Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.

The World Allergy Organization journal·2026
Same author

Immunological Basis of Chronic Spontaneous Urticaria: Immunoglobulin E and Beyond.

Yonsei medical journal·2026
Same author

What is new on the horizon for the biologics world: New kids of the block - WAO state of art.

The World Allergy Organization journal·2026
Same journal

Fecal microbiota transplantation for marked colonic dilatation.

The Korean journal of internal medicine·2026
Same journal

Opposing associations of muscle and fat mass changes on serum uric acid levels: a 2-year longitudinal cohort study.

The Korean journal of internal medicine·2026
Same journal

LncRNA as a diagnostic marker for rheumatoid arthritis: a systematic review and meta-analysis.

The Korean journal of internal medicine·2026
Same journal

Cross-neutralizing antibody responses among individuals with or without bivalent vaccine: a six-month prospective cohort study.

The Korean journal of internal medicine·2026
Same journal

Not all prediabetes is the same in its effect for bone health.

The Korean journal of internal medicine·2026
Same journal

Trabecular bone score differs among prediabetes phenotypes: the potential mediating role of visceral adiposity.

The Korean journal of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

New targets for type 2-low asthma.

Quang Luu Quoc1,2, Youngwoo Choi3, Gyu-Young Hur4

  • 1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.

The Korean Journal of Internal Medicine
|February 5, 2024
PubMed
Summary
This summary is machine-generated.

Type 2-low (T2L) asthma presents management challenges due to a lack of biomarkers. This review explores T2L characteristics and potential biologic treatments for this difficult-to-treat asthma endotype.

Keywords:
AsthmaBiomarkerMechanismNeutrophilTherapeutics

More Related Videos

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.0K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

20.7K

Related Experiment Videos

Last Updated: Jul 4, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.0K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

20.7K

Area of Science:

  • Pulmonology
  • Immunology
  • Allergy

Background:

  • Asthma involves airway obstruction and inflammation, posing diagnostic and treatment hurdles.
  • Endotype classification, particularly sputum profiles distinguishing type 2-high (T2H) and type 2-low (T2L) asthma, has advanced understanding and treatment.
  • While T2H asthma has seen successful biologic therapies, T2L asthma management remains challenging due to limited biomarkers and incomplete response to conventional treatments.

Purpose of the Study:

  • To provide insights into the clinical characteristics and underlying mechanisms of severe T2L asthma.
  • To investigate potential therapeutic strategies, particularly biologic treatments, for T2L asthma.

Main Methods:

  • Literature review focusing on severe T2L asthma.
  • Analysis of clinical characteristics and inflammatory mechanisms.
  • Exploration of current and emerging therapeutic approaches.

Main Results:

  • T2L asthma is characterized by distinct clinical features and inflammatory pathways compared to T2H asthma.
  • Current anti-inflammatory therapies offer incomplete symptom control for T2L asthma.
  • There is a critical need for novel biomarkers and targeted biologic therapies for T2L asthma.

Conclusions:

  • Severe T2L asthma requires further research to identify reliable diagnostic biomarkers.
  • Development of effective biologic treatments is crucial for improving management outcomes in T2L asthma.
  • Understanding T2L mechanisms is key to developing targeted and effective therapeutic interventions.